日本COVID-19发病预测及2023年秋季COVID-19疫苗的潜在影响
研究将美国开发的易感-暴露-感染-康复模型适配日本,预测2023年9月至2024年8月COVID-19感染、住院和死亡数,并评估2023年秋季单价XBB.1.5变异株适配疫苗对≥18岁成人的影响。
核心结论
- 结果表明,2023年秋季COVID-19疫苗将减少COVID-19相关感染、住院和死亡的总数。
研究设计与样本
- 将先前为美国开发的易感-暴露-感染-康复模型适配日本,预测2023年9月至2024年8月的COVID-19感染、住院和死亡。
- 疫苗有效性值是基于日本VERSUS检测阴性病例对照研究中二价BA.4/BA.5加强针对BA.4/BA.5的现有有效性值预测的假设值。
- 进行了敏感性分析。
主要发现
- 敏感性分析结果提示,预防的住院和死亡对初始疫苗有效性(针对感染和住院)以及针对感染的有效性衰减率最敏感。
- 预防的有症状感染对初始针对感染的有效性和有效性衰减最敏感。
局限性
- 疫苗有效性值为基于现有有效性值预测的假设值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The study objective was to estimate the incidence of COVID-19 infection, hospitalization, and deaths in Japan from September 2023 to August 2024 and potential impact of a monovalent XBB.1.5 variant-adapted Fall 2023 COVID-19 vaccine (modified version: XBB monovalent) for adults aged ≥18 years on these outcomes. METHODS: A previously developed Susceptible-Exposed-Infected-Recovered model for the United States (US) was adapted to Japan. The numbers of symptomatic infections, COVID-19-related hospitalizations, and deaths were calculated. Given differences in vaccination coverage, masking practices and social mixing patterns between the US and Japan, all inputs were updated to reflect the Japanese context. Vaccine effectiveness (VE) values are hypothetical, but predicted based on existing VE values of bivalent BA.4/BA.5 boosters against BA.4/BA.5 in Japan, from the VERSUS test-negative case-control study. Sensitivity analyses were performed. RESULTS: The base case model predicts overall that there will be approximately 35.2 million symptomatic COVID-19 infections, 690,000 hospitalizations, and 62,000 deaths in Japan between September 2023 and August 2024. If an updated COVID-19 vaccine is offered to all adults aged 18 years and older in Fall 2023, the model predicts that 7.3 million infections, 275,000 hospitalizations and 26,000 deaths will be prevented. If vaccines are only given to those aged 65 years and older, only 2.9 million infections, 180,000 hospitalizations and 19,000 deaths will be prevented. Sensitivity analysis results suggest that hospitalizations and deaths prevented are most sensitive to initial VE against infection and hospitalizations, and the waning rate associated with VE against infection. Symptomatic infections prevented was most sensitive to initial VE against infection and VE waning. CONCLUSIONS: Results suggest that a Fall 2023 COVID-19 vaccine would reduce total numbers of COVID-19-related infections, hospitalizations, and deaths.
引用
- Kohli M, Maschio M, Lee A, et al. Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine. Vaccine. 2024. PMID: 38429154. doi:10.1016/j.vaccine.2024.01.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。